All filters
Slidesets
Higher rifampicin and isoniazid concentrations in epithelial lining fluid are associated with improved response to treatment in pulmonary TB- Andrew McCallum, MBChB
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Fluoroquinolones in the treatment of multidrug-resistant tuberculosis: experience from three US TB treatment centers- Charles Peloquin, PharmD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Clofazimine pharmacokinetics in South African patients with drug-resistant tuberculosis-Sean Wasserman, MBChB, MMed
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Pharmacokinetic-Pharmacodynamic Target Attainment Analysis of Cycloserine in TB Patients- Charles Peloquin, PharmD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Treatment of Multi-Drug Resistant TB- Robert Horsburgh, MD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
High peak rifampicin concentrations accelerate the slow phase of bacterial elimination in tuberculosis patients- Antal Martinecz
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Model-based meta-analysis of rifampicin exposure and mortality in phase II tuberculosis meningitis trials- Elin Svensson
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Clinical Validation of Intracellular Pharmacodynamic (PDi) based modelling for the prediction of Fluoroquinolone activity against TB- Ghaith Aljayyoussi, PhD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Pharmacodynamic Correlates of Linezolid Activity and Toxicity in a Mouse TB Model- Kristina Bigelow, MS
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Protein binding of rifampicin is not saturated when using high-dose rifampicin- Carlijn Litjens, MSc
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Using Mycobacterium tuberculosis single nucleotide polymorphisms to predict fluoroquinolone treatment response- Timothy Rodwell, MD PhD MPH
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis- Elizabeth Tucker, MD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Kelly Dooley, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Pharmacokinetic Modeling and Simulation of the Interaction between Moxifloxacin and Rifapentine in Healthy Volunteers | M. Imperial
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Lung Tissue Concentrations of Pyrazinamide among Patients with Tuberculosis | R. Kempker
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Early interventions for diabetes related tuberculosis hasten sputum microbiological clearance in Virginia, USA | S. Heysell
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Sub-therapeutic concentrations of anti-tuberculosis drugs in children when treated according to indian dosing recommendation | B. Guiastrennec
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
A Need for altering Tuberculosis Dosing Regiments for patients with HIV-associated Tuberculous Meningitis | G. Aljayyoussi
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Lost in translation: learning from preclinical data | Gerry Davies
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis. | I. Gardner
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Application Of A Multi-Compartment Permeability-Limited Lung Model To Predict Lung Concentrations Of Moxifloxacin In Virtual Human Subjects | O. Hatley
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
The relationship between pyrazinamide pharmacokinetics (PK) and microbiologic outcomes in patients with pulmonary TB receiving standard- or high-dose rifampicin: PK/PD results from TBTC trials 27 and 28 and PanACEA MAMS | K. Dooley
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
A translational modelling and simulations approach to exploit pre-clinical tuberculosis data | S. Wicha
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling | R. Rajoli
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016